Business Wire

Hao Le Ku (Beijing) Infant and Maternity Co., Ltd. Announces the Launch in Hong Kong of Halykoo ® Line Developed by the Swiss Company APR Applied Pharma Research

Jaa

Halykoo® baby healthcare consumer products are now available in Hong Kong, promoted and commercialized by the Chinese company Hao Le Ku (HLK), as a result of an exclusive partnership with APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science driven, patent protected healthcare products.

Hong Kong baby and child-specific products market is expected to grow at a CAGR of 2% in the next years, mainly driven by the local demand and a high per capita income. Hong Kong market is very dynamic with sophisticated consumers, historically used to international brands, being very sensitive to innovative and value added products as well as looking for brands which can offer them new meaningful experiences.

Halykoo® brand, the babies’ healthcare expert, matches the request coming from such a demanding market, as its science-driven solutions are the perfect combination of Swiss, high-quality pharmaceutical expertise with an extensive understanding of child and caregivers needs.

Halykoo® offers to parents a new way for the daily healthcare of their children, by turning a potentially stressful moment into a pleasant and rewarding experience, thanks to smart and innovative product deliveries intended to simplify their use for parents and reduce the hassle for babies.

In the first phase of launching, the distribution will focus mainly on baby and health stores that offer specialized health products and health counselling. In addition, HLK will start to build up their own online store, targeting young and highly-educated parents who are digital lovers with high purchasing power. Universal Health International Group Holding Limited has been appointed by HLK as the only distributor in Hong Kong and Macao district.

Supporting Halykoo® line at best for brand building and grapping a significant share of market, HLK has carried out a comprehensive media and communication campaign, with a specific focus on online marketing as well as social networks according to the digital mindset of the potential target. In addition, special promotions will be arranged in different distribution points through trained promoters, to introduce to young mothers Halykoo® products.

“We’re investing a lot on Halykoo® launch as we mean to build up a strong brand awareness and achieve a remarkable market share in the first year,” said Mr. Ricky Ren CEO of HKL. “We really want Halykoo® to be a great success in Hong Kong as this could be the stepping stone towards Great China.”

To celebrate the launch, HLK has participated to the 25th Eugene Baby Expo, one of the biggest international B2C baby-related exhibition, from 4th to 7th August in Wan Chai. The exhibition, held twice a year, had a record of over 500,000 visits and 800 exhibitors in average, thus being the perfect showcase for Halykoo® product range.

“We are very proud to see Halykoo® products on Hong Kong stores shelves – said Mr. Paolo Galfetti, CEO of APR – and we strongly believe that Halykoo® Swiss quality products will be soon appreciated by Hong Kong consumers, in a market where baby and child-specific products saw a steady growth in 2016. ”

About Halykoo®
Halykoo®, the babies’ healthcare expert, is the first global brand offering the most comprehensive range of consumer healthcare products. It matches formulations s specifically focused on each of the main stages of children’s growth, since birth, with smart and innovative deliveries intended to simplify their use for parents and reduce the hassle for babies.

The product range has been carefully developed to solve the main daily babies’ healthcare discomforts in the major therapeutic areas for turnover such as skin care, cough & cold, eye, ear & mouth and food supplementation. As of today, the portfolio includes over 18 already developed products and 10 additional products are under development to be finalized in 2018.

Conceived and formulated applying the value of Swiss pharmaceutical expertise, Halykoo provides science-driven pediatric solutions that perfectly combine smart deliveries, thanks to the application of the pharmaceutical technology knowledge, with advanced formulations, balanced on the physiological babies’ needs.

For more info about Halykoo®, please visit: www.halykoo.com

About Hao Le Ku (Beijing) Infant and Maternity Co., Ltd.
Hao Le Ku is a leading company engaged in marketing of baby products. We are a service oriented, high quality and ethically-driven. Our company was founded in 2013 and registered in Tian Jin, China. Our revenue has been increasing significantly during the last 2 years and the growth rate recorded is more than 100%. Our baby protection products covered many different categories in the industry.

About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science-driven, patent protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products commercialized in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.
For more information please visit www.apr.ch or www.halykoo.com

Contact information

APR Applied Pharma Research s.a.,
Paolo Galfetti; CEO
T: +41 91 6957020
email to paolo.galfetti@apr.ch
or
Hao Le Ku (Beijing) Infant and Materniity Co., Ltd.
Ricky Ren; CEO
T: +1 (626) 328-9241
email to renhongguang@halykoo.com.cn
or
Havas PR Milan - Press Office
Sara Bernabovi
T: +39 02 85457032 or email to
sara.bernabovi@havaspr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Rimini Street Expands Investment and Operations in Europe19.10.2017 01:00Tiedote

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy19.10.2017 00:43Tiedote

Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which

IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 23:15Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu

Sparkol Launches VideoScribe 318.10.2017 16:24Tiedote

Introducing VideoScribe Version 3 by Sparkol. Already used by over two million people across the world to create engaging explainer videos, Version 3 of the highly intuitive software comes packed full of new features, including: An improved user experience and slick UI - animate easier than ever before Enhanced search - find exactly the image you need in record time Intelligent image recommendations - focus your creativity on your video instead Smoother performance - maximum productivity when using the software VideoScribe customers include the world’s largest brands (HP, BBC, Sky and the University of British Columbia), businesses across every sector, leading education providers, award-winning teachers, charities, campaigners, and coun

Piraeus Bank: Agreement for the Sale of Serbian Operations18.10.2017 16:06Tiedote

Piraeus Bank announces that it has entered into an agreement to sell its Serbian banking and leasing operations to Direktna Banka A.D., a local Serbian banking group that has been strongly growing its presence in the market, for a total cash consideration between €58mn up to €61mn, depending on the financial performance of the divested assets until completion of the transaction, through a combination of direct sale price and simultaneous reduction of capital in Piraeus Bank Beograd AD. The transaction is conditional upon the usual corporate and regulatory approvals, including those of the National Bank of Serbia and the Hellenic Financial Stability Fund. The transaction represents another step towards the implementation of Piraeus Bank’s Restructuring Plan commitments, as those were agreed with the Directorate General of Competition of the European Commission. The transactio

Introducing InVision Studio, The World’s Most Powerful Screen Design Tool18.10.2017 16:01Tiedote

InVision, the product design platform powering the world’s best digital experiences, today introduced Studio, a powerful new tool that will change the way screen design is done. InVision Studio was created by working closely with the world’s best design teams and finding inspiration in how they create beloved digital products. The launch of Studio comes at a time when modern organizations are shaping and redefining entire markets through their focus on digital customer experience. InVision already powers the product design process of more than 3 million people at tens of thousands of companies, including eighty percent of the Fortune 100 and brands like Airbnb, Uber, HBO, Amazon, IBM, Nike, and Slack. This new product reflects a major evolution of the digital product design workflow. With Studio, InVision has developed an end-to-end platform for designing digit

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme